NCT06089382
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Recurrence-Free Survival (RFS)
Timeframe: Randomization up to approximately 36 months
Secondary (5)
RFS Rate at 12 and 24 Months
Overall Survival (OS)
Adverse events (AEs)
Quality of Life (QoL) Scale Score
Hepatocellular Carcinoma Module (EORTC QLQ-HCC18) Scale Score
Arms and interventions
Sintilimab Plus LenvatinibExperimental
TACE(one cycle) + active surveillanceActive comparator
Drugs: Sintilimab, Lenvatinib
Procedures: Transarterial Chemoembolization (TACE)
Sites
1 site in 1 country
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, China